MAD Ventures

MAD Ventures is a management firm and venture capital incubator based in Victoria, Canada, dedicated to supporting growing Canadian businesses. The firm provides financial backing and expertise, focusing on seed, early stage, and later stage investments. MAD Ventures primarily targets the healthcare and technology sectors, aiming to foster innovation and development within these industries.

Thomas Ahn

Founder and CEO

3 past transactions

BagIt Solutions

Funding Round in 2022
Tasteport is an online food technology platform designed to enhance the way people discover, access, and share diverse culinary experiences. The company empowers specialty grocers by providing an ecosystem that enables them to transition to an e-grocery model. Through its platform, Tasteport facilitates the exploration and ordering of thousands of local, specialty, and international groceries, allowing consumers to enjoy global flavors delivered to their homes. By leveraging innovative technology, Tasteport aims to streamline the fulfillment process for grocers, ensuring efficient service and a wide variety of fresh options for customers, anytime and anywhere.

Swarm Analytics

Venture Round in 2021
Swarm Analytics is a developer of an artificial intelligence platform that specializes in low-footprint video analysis algorithms utilizing deep learning. The company has created a plug-and-play framework for computer vision tasks that can be seamlessly integrated into various devices, from small embedded systems like Raspberry Pi and FPGA-based devices to distributed server clusters with multiple GPUs. Swarm Analytics' platform provides hyper-local and real-time data on urban traffic and transport, addressing critical issues in security, surveillance, logistics, and transportation. This capability enables clients to effectively tackle significant challenges related to information sourcing in traffic and parking insights.

Indel Therapeutics

Series B in 2011
Indel Therapeutics Inc. is a Vancouver‐based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult‐to‐treat and hospital‐acquired infections. These programs are based on Indel's paradigm‐changing antimicrobial drug discovery platform, a patented technology that that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases and has the potential to provide an advantage against drug resistance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.